John LeGall, MD, MBA

John LeGall is Vice President Clinical Development at Allogene Therapeutics. At Allogene, Dr. LeGall is serving as the principal investigator of ALLO-316, an allogeneic CAR-T cell therapy. Prior to Allogene, Dr. LeGall has held multiple leadership roles across the Cell and Gene Therapy space. He has served in clinical development roles at Instil Bio focused on development of TIL therapies and at Kite Pharma focused on CAR-T cell therapies. Dr. LeGall received his MD from Columbia University and MBA from Columbia Business School, and completed a clinical fellowship in Oncology and Hematology at Johns Hopkins Hospital and Immunotherapy at the National Cancer Institute.

Rizwan Romee, MD

Dr. Rizwan Romee is an Associate Professor of Medicine at Harvard Medical School and Director of the Haploidentical Donor Transplant Program at Dana-Farber Cancer Institute. A translational physician-scientist and oncologist, his research focuses on advancing NK cell–based immunotherapies for cancer. His laboratory employs innovative synthetic biology tools, including both CRISPR and non-CRISPR gene-editing technologies, to enhance NK cell anti-tumor function. He also leads the Dana-Farber NK Cell Therapeutics Initiative, driving the development of next-generation cellular therapies.

Shawn Rose, MD, PhD

Shawn Rose, MD, PhD, is Chief Medical Officer (CMO) and Head of Research & Development at Nkarta Inc. During his career, Dr. Rose has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such as Sotyktu™, Stelara™ and Tremfya™.

As Chief Development Officer, Immunology at Vividion Therapeutics, Dr. Rose led the Vividion and Bayer strategy to advance a portfolio of novel immunology assets targeting previously undruggable proteins. As Senior Vice President and Head of the Clinical Development Organization at Magenta Therapeutics, he developed cell-based therapeutics for patients with cancer, genetic disorders, and autoimmune diseases. At Annexon Biosciences, he led autoimmunity clinical development.

Dr. Rose served as Senior Director of Immunology Translational Science and Medicine (TSM) at Johnson & Johnson (J&J), where he headed the clinical team responsible for the design and execution of early clinical studies. At J&J, he also served as the disease area strategic leader for rheumatology and autoimmunity within TSM, led a registrational program in systemic lupus erythematosus, and was Stelara compound development team leader for rheumatologic indications. Prior to joining J&J, Dr. Rose was at Bristol-Myers Squibb (BMS), where he led clinical development programs as a director within BMS Immunoscience and co-chaired the Translational Research and Development Committee.

Dr. Rose was an attending physician at the NIH Clinical Center and volunteered at multiple community clinics in the Washington D.C. area. He completed his internal medicine residency and clinical and research fellowship in the Rheumatology Division at Northwestern University. Dr. Rose has been an R&D and corporate advisor to biotech companies and venture capital firms, helped to launch new biotech companies, and has served on multiple scientific advisory boards. He enjoys mentoring youth as well as the next generation of physicians, scientists, and biotech and pharmaceutical leaders in their career journey.

Shana Topp, PhD

Shana Topp is a Managing Director and Partner at Boston Consulting Group, where she leads work in biopharma and advanced modalities, helping companies scale novel therapies such as CAR-T, RNA, and gene therapies from clinical development to commercial delivery. With a PhD in Chemistry from Emory University and more than a decade at BCG, she combines deep scientific expertise with strategic and operational insight, advising clients on manufacturing, supply chain, and digital transformation. She has co-authored BCG thought leadership on RNA therapeutics, next-generation CAR-T therapies, and novel therapy operations, and is recognized for bridging cutting-edge science with the business models and technical capabilities needed to bring transformative treatments to patients at scale.

Hussain Mooraj

Hussain Mooraj is a Principal at Deloitte Consulting LLP and the Global NextGen Therapy Practice Lead as well as the Life Sciences leader for New England. He partners with industry executives to design and scale patient‑first value chains for cell and gene therapies (CGTs), integrating operating models, digital orchestration, clinical‑trial supply, and commercial readiness. With more than 25 years across manufacturing, supply chain, enterprise technology, sales & marketing, and strategy consulting, Hussain has led transformations spanning control‑tower programs, ERP rollouts, and global logistics for complex, highlyregulated environments.​

​Recognized as a trusted advisor and industry voice, he contributes regularly to industry publications and forums—from Deloitte Insights and American Pharmaceutical Review to Cell & Gene, PharmaBoardroom, Kinaxis’ Big Ideas in Supply Chain, and Deloitte’s TECHTalks podcast—where he champions pragmatic, patient‑centric solutions that help science become scalable business.​